Foghorn Therapeutics

Foghorn Therapeutics is a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression. Our innovative approaches target the chromatin regulatory system that plays a vital role in gene expression, enabling us to develop therapeutics that can address the unmet needs in oncology and other disease areas. Utilizing our proprietary Gene Traffic Control® platform, we have the capability to understand and manipulate gene behavior, allowing us to harness the chromatin system's potential for therapeutic intervention.

Our team comprises experts with vast experience in biotechnology and drug development, committed to transforming the lives of patients through groundbreaking therapies. Foghorn is focused on advancing a robust pipeline of product candidates, with several under clinical development across a range of cancers. By employing precision medicine strategies, we are well-positioned to deliver innovative treatments that may significantly improve patient outcomes. Our mission underscores a relentless pursuit of scientific excellence while fostering a culture that promotes collaborative innovation.